Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001104659-20-070680
Filing Date
2020-06-08
Accepted
2020-06-08 09:18:54
Documents
10

Document Format Files

Seq Description Document Type Size
1 424B4 tm2019773-4_424b4.htm 424B4 3520002
2 GRAPHIC lg_calliditas.jpg GRAPHIC 39217
3 GRAPHIC tv538694_chrt-pipeline1.jpg GRAPHIC 34161
4 GRAPHIC tv537685_chrt-peyers2.jpg GRAPHIC 1964138
5 GRAPHIC tv533987_chrt-nefecon.jpg GRAPHIC 55665
6 GRAPHIC tv533987_twocomponents2.jpg GRAPHIC 177021
7 GRAPHIC tv533987_chrt-placebo.jpg GRAPHIC 45189
8 GRAPHIC tv533987_chrt-stabilization.jpg GRAPHIC 44321
9 GRAPHIC tv533987_proteinuria.jpg GRAPHIC 69176
10 GRAPHIC tv533987_chrt-summary.jpg GRAPHIC 44105
  Complete submission text file 0001104659-20-070680.txt   6806562
Mailing Address KUNGSBRON 1, C8 STOCKHOLM V7 SE-111 22
Business Address KUNGSBRON 1, C8 STOCKHOLM V7 SE-111 22 46 8411 3005
Calliditas Therapeutics AB (Filer) CIK: 0001795579 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V7 | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-238244 | Film No.: 20948246
SIC: 2834 Pharmaceutical Preparations